Nurix Therapeutics Inc
NRIXHealthcare|Biotechnology|USA
$23.08
-1.63 (-6.60%)
Tangible Book
$3.88
Upcoming Data Readouts (3)
Aug 2026
Est. completion
Jan 2027
Est. completion
P1Chronic Lymphocytic Leukemia (CLL)
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022n=572
Jan 2028
Est. completion
P2Chronic Lymphocytic Leukemia (CLL)
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500n=100